BU-02152 AN EVALUATION OF THE PRESCRIPTION PATTERN OF IDegAsp AND ITS CLINICAL OUTCOMES IN INDIAN CLINICAL PRACTICE

International
Diabetes
Federation

OP-0543

J.KESAVADEV¹, B. SABOO², S.JOSHI³, A.SHANKAR¹, A.DAVID¹, L.RAMACHANDRAN¹, S.JOTHYDEV¹

1. JOTHYDEV'S DIABETES RESEARCH CENTRE, THIRUVANATHAPURAM, KERALA, INDIA 2. DIA CARE - DIABETES CARE & HORMONE CLINIC, AHMEDABAD, GUJARAT, INDIA
3. LILAVATI HOSPITAL, BHATIA HOSPITAL, JOSHI CLINIC, MUMBAI, INDIA

www.jothydev.net, www.research.jothydev.com, jothydev@gmail.com

BACKGROUND

IDegAsp, the first soluble co-formulation which contains 70% basal IDeg and 30% mealtime IAsp, has a unique pharmacodynamic profile. Postprandial and fasting hyperglycemia can be effectively controlled, without increasing the hypoglycemia risk. IDeg component provides a stable basal insulin action over a 24-h period whereas the IAsp component bestows prandial control, which is unaffected by the basal component.

AIMS

A retrospective evaluation of the prescription pattern and the clinical outcomes of IDegAsp among T2DM subjects in a real-world setting of Indian clinical practice.

METHODS

Clinical characteristics and demographics of T2DM subjects prescribed with IDegAsp and on regular follow-up were captured from our EMRs. n=291, age=53.59±11.80years, T2DM duration=11.05±6.28years, 74.14% males, IDegAsp treatment duration (as on 1st April 2018)=10.51±8.53months. Previous treatment regimen of the patients: (1) OHA only, n=87; (2) OHA+insulin, n=176; (3) OHA+Insulin+GLP1RA, n=7 [3 patients discontinued GLP1RA upon IDegAsp initiation]; (4) Treatment naïve [started on IDegAsp+OHAs, n=17; started on IDegAsp+OHAs+GLP1RA, n=4].

RESULTS

IDegAsp treatment resulted in significant improvement in the clinical profiles. Overall reduction from baseline: FBS -34.93 mg/dL, p<0.0001; PPBS -65.09, p<0.0001; HbA1c -1.470, p<0.0001. Changes in Body weight, BMI and TDD of insulin were non-significant. Negligible number of hypoglycemic episodes reported (0.007 events/ person, none severe, no nocturnal hypos). Initially, 32.88% and 67.12% of the subjects were on IDegAsp once daily(q.d) and twice daily(b.i.d.) respectively. Later, 22.92% of the subjects in the q.d regimen had to be intensified to b.i.d. and 3.57% of the subjects in the b.i.d. were shifted to q.d.

Previous treatment regimen before initiating IDegAsp(n)	Age (Years)	Males (%)	T2DM duration (Years)	IDegAsp treatment duration(Months)	FBS (mg/dL)			PPBS (mg/dL)			HbA1c (%)		
					Baseline	Recent visit	Baseline change, P value Baseline vs. Recent visit	Baseline	Recent visit	Baseline change, P value Baseline vs. Recent visit	Baseline	Recent visit	Baseline change, P value Baseline vs. Recent visit
Patients previously on OHA only (87)	51.63±10.55	74.71	10.6±6.99	9.27±8.17	183.67±61.86	138.28±40.01	-45.39, <0.0001	303.33±38.40	175.98±55.99	-127.4, <0.0001	9.32±2.05	7.34±0.92	-1.972, <0.0001
Patients previously on OHA+Insulin (176)	54.94±12.14	73.3	11.38±5.83	11.31±8.65	159.78±56.79	138.14±38.85	-21.64, <0.0001	209.13±89.90	167.32±51.15	-41.81, <0.0001	8.53±1.79	7.45±0.95	-1.078, <0.0001
Patients previously on OHA+Insulin+GLP1RA (7)	49.29±12.92	85.71	8.83±5.81	13.00±9.75	180.00±46.46	121.14±19.89	-58.86, 0.0095	206.57±70.19	131.00±40.54	-75.57, 0.0297	9.17±2.03	7.18±1.07	-1.991, 0.0405
Treatment naïve. Patients started on IDegAsp+OHAs (17)	51.82±13.32	76.47	11.23±7.77	8.53±8.35	249.00±87.05	150.21±53.48	-98.79, 0.0004	354.33±83.6	184.11±59.56	-170.20, <0.0001	10.88±2.88	9.63±3.19	-1.242, 0.2425
Treatment naïve. Patients started on IDegAsp+OHAs+GLP1RA (4)	54.50±7.78	50	9.00±8.49	5.00±4.24	145.00±39.60	121.00±41.01	-24.00, 0.4321	348.23±56.78	215.00±37.58	-133.20, 0.0079	10.30±1.56	8.88±0.65	-1.420, 0.1431
All subjects (291)	53.59±11.80	74.14	11.05±6.28	10.51±8.53	173.18±63.90	138.25±39.61	-34.93, <0.0001	235.21±98.63	170.12±53.08	-65.09, <0.0001	8.97±2.05	7.50±1.16	-1.470, <0.0001

DISCUSSION

In this real-world study of Indian clinical practice, prescription data indicated that the IDegAsp co-formulation is effective across a range of clinical profiles including treatment naïve subjects. It significantly improved clinical outcomes, with negligible hypoglycemia and no weight gain. To a greater extent, IDegAsp could thus help eliminate the concerns regarding insulin intensification such as fear of injections and burdensome regimens, thereby overcome clinical inertia and achieve clinical outcomes in a large proportion of T2DM individuals.

REFERENCES

- Haahr H, Fita EG, Heise T. A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use. Clin Pharmacokinet. 2017 Apr;56(4):339-354.
- J.Kesavadev, B.Saboo, A.Shankar, A.David, R.Warrier et al. IDegAsp Improves Glycemic Control with Minimal Hypoglycemia—An Indian Real-World Study in T2D Subjects. Diabetes 2018 Jul; 67(Supplement 1).